FDA approves First RSV vaccine for adults under 60
FDA Expands Approval of RSV Vaccine Abrysvo to Include All At-Risk Adults
The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in high-risk adults ages 18 to 59 years, Pfizer announced on Tuesday.
The campaign “caused Americans to lose trust in the public health system,” House Energy and Commerce Committee Chair Cathy ...
Nearly 10.4M New Yorkers, or 53%, got the flu shot last year. Only about 12% got the COVID shot. Here's why, how officials ...
The naturally occurring form of polio remains active in only two countries in the world: Pakistan and Afghanistan. Over 50 ...
The BBC's Fergus Walsh hears from those calling for the payment system set up to help those left disabled after having a ...
A vaccine against fentanyl—yes! Finally, a truly novel approach to SUDs is currently under development and hopefully will ...
A norovirus vaccine based on the mRNA technology that helped to defeat Covid will be trialled in the UK for the first time, ...
The Oxford AstraZeneca vaccine is credited with saving millions of lives but it was also responsible, in rare cases, for ...
Medpage Today on MSN1d
Mpox Vaccine in Teens Generates Robust Immune Response, Proves SafeThe modified vaccinia Ankara-Bavarian Nordic mpox vaccine (MVA-BN; Jynneos) generated robust immune responses in adolescents ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback